ATOSSA THERAPEUTICS, INC. (ATOS): Nasdaq/NYSE listing notice — Atossa Therapeutics receives Nasdaq extension to Feb 17, 2026 for bid price compliance

ATOSSA THERAPEUTICS, INC.

Nasdaq notified Atossa on Feb 21, 2025 of non-compliance with $1.00 min bid price rule.
Initial compliance period ended Aug 20, 2025; extension granted to Feb 17, 2026.
Company may consider a reverse stock split to regain compliance.
No immediate impact on Nasdaq listing or trading of ATOS shares.
Atossa is monitoring bid price and evaluating available options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company’s initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was inf

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-110654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.